Key Points - Robbins LLP reminds Capricor Therapeutics, Inc. stockholders of the securities fraud class action after the company's stock fell 64%. - Kaplan Fox is investigating allegations that Capricor Therapeutics, Inc. misled investors regarding the path to FDA approval for Deramioce. - Investors who suffered losses in Capricor Therapeutics, Inc. are encouraged to seek...
Vaxart, Inc. (VXRT) opened with a modest down gap of 1.6% on 2026-09-10, leaving a void...
Parke Bancorp, Inc. (PKBK) gives both camps something to hold. These are the 3 bullish and...
Spok Holdings, Inc. (SPOK) gives both camps something to hold. These are the 4 bullish and...
Every position is an argument with someone on the other side. Here is what the numbers...
from Canaccord Genuity issued a price target of $2.00 for ARBE on 2026-09-11 11:03:47.The adjusted price target was set to $2.00.At the time of the announcement, ARBE was trading at...
Raghuram Selvaraju from H.C. Wainwright issued a price target of $5.00 for OVID on 2026-09-11 10:14:13.The adjusted price target was set to $5.00.At the time of the announcement, OVID was...
from Wedbush issued a price target of $5.00 for TLS on 2026-09-10 20:11:11.The adjusted price target was set to $5.00.At the time of the announcement, TLS was trading at $4.68.The...
from Telsey Advisory issued a price target of $23.00 for JILL on 2026-09-10 14:31:25.The adjusted price target was set to $23.00.At the time of the announcement, JILL was trading at...
Kristen Kluska from Cantor Fitzgerald issued a price target of $11.00 for AQST on 2026-09-10 13:31:00.The adjusted price target was set to $11.00.At the time of the announcement, AQST was...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
